Premium
P1‐356: S100B, but not NSE, serum levels differentiate mild from severe Alzheimer's disease patients
Author(s) -
Chaves Marcia L.
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.05.938
Subject(s) - enolase , medicine , dementia , alzheimer's disease , gastroenterology , venipuncture , disease , clinical dementia rating , pathology , surgery , immunohistochemistry
Diagnosis: We compared the blood biomarker concentration of 94 patients with propable AD (pAD) and of 53 healthy controls. Prognosis: 131 MCI patients were followed up for 5 years. The prognostic (endpoint: ADconversion) value of baseline blood biomarker concentration was calculated. Results: Diagnosis: Both peptides were significantly increased in pAD-patients. At a Specificity of 80%, the Sensitivity for MR-ProANP was 63% (AUC 0.741, p 0.0001) and for MR-ProADM 47% (AUC 0.654, p 0.002). Prognosis During the observation period, 75 (57% of all patients) converted to pAD. Baseline MR-ProANP and MR-ProADM are significantly (p 0.0001) increased in the converter group. The AUC for the prognosis of conversion at 60 month was 0,79 for MR-ProANP and 0,7 for MR-ProADM. Conclusions: These data indicating the possible use of MR-ProANP and MR-ProADM as an aid in the diagnosis and prognosis of AD/MCI and support a possible role of circulatory dysfunction in the development of AD.